CTOs on the Move

Ewald Consulting

www.ewald.com

 
Ewald Consulting is a Saint Paul, MN-based company in the Business Services sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ewald.com
  • 1000 Westgate Dr
    Saint Paul, MN USA 55114
  • Phone: 651.290.7495

Executives

Name Title Contact Details

Similar Companies

Huffman Associates

Huffman Associates is a Bay Shore, NY-based company in the Business Services sector.

MarketingProfs

MarketingProfs, founded in 2000, is a comprehensive learning site for marketing professionals, with more than 185,000 members worldwide. Drawing on the expertise of more than 300 analysts, marketing professionals, and professors, MarketingProfs helps

East Point Solutions

East Point Solutions Corp. is a Lindenhurst, NY-based company in the Business Services sector.

Progressive Waste Solutions

Progressive Waste Solutions Ltd. is one of North America`s largest full-service, vertically integrated waste management companies, providing non-hazardous solid waste collection and landfill disposal services to commercial, industrial, municipal and residential customers in twelve states and the District of the Columbia in the U.S., and six Canadian provinces. The Company`s shares are listed on the New York and Toronto Stock Exchanges under the symbol BIN.

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.